Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain

This study has been terminated.
(No patients were enrolled in this study. The study onset was delayed due to problems with drug acquisition.)
Sponsor:
Information provided by:
Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00425230
First received: January 19, 2007
Last updated: December 21, 2010
Last verified: December 2010

January 19, 2007
December 21, 2010
January 2007
Not Provided
McGill Short Form Pain Questionairre
Same as current
Complete list of historical versions of study NCT00425230 on ClinicalTrials.gov Archive Site
  • Fiser Side effect scale
  • visual analog pain scale
  • Present Pain intensity
  • Tylenol # 3 consumption
Same as current
Not Provided
Not Provided
 
Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain
Pilot Study of Use of Duloxetine for the Treatment of Phantom Limb Pain

This is a study to assess the possible benefit of duloxetine in the treatment of chronic phantom limb pain.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Chronic Phantom Limb Pain
Drug: Duloxetine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
15
June 2007
Not Provided

Inclusion Criteria:

  1. Chronic PLP > 6 months
  2. Short-Form McGill Pain Questionnaire Sensory Pain Rating Index raw score ≥ 16
  3. Age ≥ 18 years old
  4. Inpatient or Outpatient
  5. Able to come to all appointments, in the opinion of the investigator
  6. Able to give informed consent, in opinion of investigator

Exclusion Criteria:

  1. Current Major Depressive disorder, Anxiety Disorder, or Psychotic disorder assessed by the Mini International Neuropsychiatric Interview (MINI)
  2. Substance abuse or dependence within the last six months, as assessed by the MINI
  3. Known Diabetes Mellitus to exclude diabetic peripheral neuropathy
  4. History of coronary artery disease, hepatic disease, renal disease
  5. Other pain syndromes
  6. Any unstable medical conditions in the opinion of the investigator
  7. Other psychotropic medications excluding hypnotics
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00425230
06J02H
Not Provided
Not Provided
Baylor College of Medicine
Not Provided
Principal Investigator: Asif Chaudhry, MD Baylor College of Medicine
Baylor College of Medicine
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP